罗格列酮联合胰岛素治疗2型糖尿病的血糖、血脂改善效果及观察

Effect Observation of Rosiglitazone Combined with Insulin in Treatment of Type 2 Diabetes on Blood Sugar and Blood Lipids Improvement

目的:研究罗格列酮联合胰岛素治疗2型糖尿病的血糖、血脂改善效果及安全性。方法:315例2型糖尿病患者按入院先后顺序分为观察组(157例)和对照组(158例)。对照组予门冬胰岛素30注射液,观察组在对照组基础上加用罗格列酮片。两组患者疗程均为3个月。观察两组患者治疗前后糖化血红蛋白(Hb A1c)、血糖(FBG、2h PG)、血脂(TG、TC、HDL-C、LDL-C)等指标变化,以及药品不良反应发生情况,比较两组胰岛素用量和血糖达标时间。结果:治疗后,两组FBG、2h PG和Hb A1c均较治疗前降低(P<0.05),且观察组患者各项指标均低于对照组(P<0.05)。治疗后,两组患者TG、TC、LDL-C均较治疗前下降(P<0.05),而HDL-C无明显变化(P>0.05)。观察组治疗后TG、TC水平显著低于对照组(P<0.05),而两组治疗后LDL-C、HDL-C水平比较,差异无统计学意义(P>0.05)。治疗后,观察组胰岛素用量显著低于对照组,血糖达标时间也明显短于对照组(P<0.05)。两组低血糖事件和药品不良反应发生例数比较,差异无统计学意义(P>0.05)。结论:罗格列酮联合胰岛素治疗2型糖尿病,可显著改善患者的血糖、血脂指标,减少胰岛素用量,缩短血糖达标时间,且安全性较高,值得广泛推广使用。

Objective： To study the effectiveness and safety of rosiglitazone combined with insulin therapy on type 2 diabetes, and the improvement on blood sugar and blood lipids. Methods：315 cases of type 2 diabeteswere divided into observation group （ 157 cases） and control group （ 158 cases） at random. The control group was given insulin aspart 30 injection, while,observation group was additionally given rosiglitazone. Two groups of patients both with a course of three months. Before and after treatment, HbA1 c, blood sugar（ FBG, 2hPG）, blood lipids （ TG, TC, HDL-C, LDL-C） , and the ad- verse drug reactions were observed. Meanwhile ,the amount of insulin and blood glucose time of two groups＇ patients were compared. Results：After treatment, FBG,2hPG,HbAlc in patients of two groups were all reduced than before（P 〈0.05）, and the levels on patients of observation group were significantly lower than that of control group （ P 〈 0.05 ）. TG, TC, LDL-C in patients of two groups were all reduced than before （P 〈 0.05 ）, while HDL-C had no obvious change （ P 〉 0.05 ）. After treatment,TG,TC levels of observation group were significantly lower than the control group （P 〈 0.05 ）, although HDL-C and LDL-C levels of the two groups after treatment had no significant differences （ P 〉 0.05 ）. The amount of insulin in patients in the observation group was significantly lower than the control group, and blood glucose standard time was also significantly shorter than the control group（P 〈0.05）. There were no significant differences on the cases of hypoglycemic events or adverse drug reactions between the two groups. Conclusion： Rosiglitazone combined with insulin in the treatment of type 2 diabetes, the patient＇s blood glucose, lipids can be significantly improved, and fewer adverse reactions, with high security,. It deserve widely used.